Cosmetic cross-reference Noindex: medium evidence

273203-62-6

CAS 273203-62-6

273203-62-6 (CAS 273203-62-6) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
273203-62-6
CAS Number
273203-62-6
UNII
8QWM6I035C
InChIKey
TVGLGJWCZSCAEM-UHFFFAOYSA-N
ChEMBL ID
CHEMBL4303439
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
MYRISTYL NICOTINATE
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
MYRISTYL NICOTINATE 1425406 SU MTHSPL
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 273203-62-6 used for in pharmaceutical contexts?

273203-62-6 (CAS 273203-62-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 273203-62-6?

No adverse-event association or SIDER side-effect rows are rendered for 273203-62-6 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 273203-62-6 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for MYRISTYL NICOTINATE with EU status "permitted".

What clinical phase is 273203-62-6 in?

No phase 1-4 clinical development badge is rendered for 273203-62-6 because the matched compound identifier rows do not contain a max-phase value.